These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 16504579

  • 1. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%.
    Pitt B, Gheorghiade M, Zannad F, Anderson JL, van Veldhuisen DJ, Parkhomenko A, Corbalan R, Klug EQ, Mukherjee R, Solomon H, EPHESUS Investigators.
    Eur J Heart Fail; 2006 May; 8(3):295-301. PubMed ID: 16504579
    [Abstract] [Full Text] [Related]

  • 2. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
    Gheorghiade M, Khan S, Blair JE, Harinstein ME, Krum H, Mukherjee R, Pitt B, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival (EPHESUS) Investigators.
    Am Heart J; 2009 Sep; 158(3):437-43. PubMed ID: 19699868
    [Abstract] [Full Text] [Related]

  • 3. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
    Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J, EPHESUS Investigators.
    J Am Coll Cardiol; 2005 Aug 02; 46(3):425-31. PubMed ID: 16053953
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH, Abuissa H, Pitt B.
    Diabetes Obes Metab; 2008 Jun 02; 10(6):492-7. PubMed ID: 17490427
    [Abstract] [Full Text] [Related]

  • 6. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators.
    N Engl J Med; 2003 Apr 03; 348(14):1309-21. PubMed ID: 12668699
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, EPHESUS Investigators.
    Circulation; 2008 Oct 14; 118(16):1643-50. PubMed ID: 18824643
    [Abstract] [Full Text] [Related]

  • 11. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
    Butler J, Ezekowitz JA, Collins SP, Givertz MM, Teerlink JR, Walsh MN, Albert NM, Westlake Canary CA, Carson PE, Colvin-Adams M, Fang JC, Hernandez AF, Hershberger RE, Katz SD, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Stough WG, Starling RC.
    J Card Fail; 2012 Apr 14; 18(4):265-81. PubMed ID: 22464767
    [Abstract] [Full Text] [Related]

  • 12. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
    Naser N, Durak-Nalbantic A, Sabanovic-Bajramovic N, Karic A.
    Med Arch; 2023 Apr 14; 77(2):105-111. PubMed ID: 37260796
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.
    Adamopoulos C, Ahmed A, Fay R, Angioi M, Filippatos G, Vincent J, Pitt B, Zannad F, EPHESUS Investigators.
    Eur J Heart Fail; 2009 Nov 14; 11(11):1099-105. PubMed ID: 19875410
    [Abstract] [Full Text] [Related]

  • 15. Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?
    Weir RA, Mark PB, Petrie CJ, Clements S, Steedman T, Ford I, Ng LL, Squire IB, Wagner GS, McMurray JJ, Dargie HJ.
    Am Heart J; 2009 Jun 14; 157(6):1088-96. PubMed ID: 19464421
    [Abstract] [Full Text] [Related]

  • 16. Usefulness of matrix metalloproteinase-9 plasma levels to identify patients with preserved left ventricular systolic function after acute myocardial infarction who could benefit from eplerenone.
    Kampourides N, Tziakas D, Chalikias G, Papazoglou D, Maltezos E, Symeonides D, Konstantinides S.
    Am J Cardiol; 2012 Oct 15; 110(8):1085-91. PubMed ID: 22742718
    [Abstract] [Full Text] [Related]

  • 17. Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) substudy.
    Regnault V, Lagrange J, Pizard A, Safar ME, Fay R, Pitt B, Challande P, Rossignol P, Zannad F, Lacolley P.
    Hypertension; 2014 Jan 15; 63(1):105-11. PubMed ID: 24126172
    [Abstract] [Full Text] [Related]

  • 18. Eplerenone in chronic heart failure with depressed systolic function.
    Volterrani M, Iellamo F.
    Int J Cardiol; 2015 Dec 01; 200():12-4. PubMed ID: 26044084
    [Abstract] [Full Text] [Related]

  • 19. Adherence to aldosterone-blocking agents in patients with heart failure.
    Margolis J, Gerber RA, Roberts C, Gheorghiade M.
    Am J Ther; 2010 Dec 01; 17(5):446-54. PubMed ID: 20844344
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective.
    Szucs TD, Holm MV, Schwenkglenks M, Zhang Z, Weintraub WS, Burnier M, Erne P.
    Cardiovasc Drugs Ther; 2006 Jun 01; 20(3):193-204. PubMed ID: 16775667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.